Demyelinating Disease
Demyelinating diseases are conditions in which the protective myelin surrounding nerve fibers is damaged, disrupting normal nerve signal transmission. This category includes several distinct inflammatory neurological conditions.
Some inflammatory demyelinating disorders are associated with specific antibodies that can help doctors distinguish between different neurological conditions — most notably neuromyelitis optica spectrum disorder (NMOSD) and MOG-associated disease (MOGAD), which can present similarly to other demyelinating conditions but require different management approaches.
At National Path Lab (NPL), specialized antibody testing supports the evaluation of selected patients with inflammatory neurological presentations, helping guide accurate diagnosis and treatment planning by a neurologist.
About Demyelinating Disease
Causes & Risk Factors
The exact cause of inflammatory demyelinating diseases is not fully understood, but they are believed to involve an abnormal immune response directed against components of the nervous system.
• Autoimmune mechanism — the immune system mistakenly targets myelin or specific proteins associated with nerve cells (such as aquaporin-4 or myelin oligodendrocyte glycoprotein).
• Age — many inflammatory demyelinating conditions commonly present in young adults, though they can occur at other ages.
• Sex — NMOSD, in particular, is markedly more common in women than men.
• Genetic and environmental factors — a combination of genetic susceptibility and environmental factors (including some infections) is thought to contribute, though no single cause has been identified.
• Coexisting autoimmune disease — some patients with demyelinating disease also have other autoimmune conditions, such as SLE or Sjögren syndrome.
Symptoms & When to Test
Symptoms depend on which part of the nervous system is affected, and can range from visual disturbance to limb weakness.
• Optic neuritis — eye pain and vision loss or blurring, often in one eye
• Longitudinally extensive transverse myelitis — weakness, numbness, or bladder/bowel dysfunction due to spinal cord inflammation
• Acute disseminated encephalomyelitis (ADEM) — confusion, weakness, or multifocal neurological symptoms, more common in children
• Limb weakness or numbness
• Bladder or bowel dysfunction
• Balance or coordination difficulties
When Should You Consider Testing?
Anti-NMO/AQP4 and Anti-MOG testing are typically considered in selected patients with characteristic presentations such as optic neuritis, longitudinally extensive transverse myelitis, or ADEM — not for general or nonspecific neurological symptoms — and are usually ordered by a neurologist as part of a focused work-up.
Why Tests Are Combined
Anti-NMO/AQP4 and Anti-MOG antibodies identify distinct, separate conditions (NMOSD and MOGAD respectively) that can look clinically similar but have different treatment approaches and prognoses — testing both allows the neurologist to distinguish between them rather than assuming a single diagnosis.
These antibodies are typically tested together with clinical assessment, MRI findings, and sometimes cerebrospinal fluid analysis (including IgG synthesis index/rate), since no single antibody test is used in isolation to confirm a demyelinating disease.
Because inflammatory demyelinating diseases can resemble other neurological conditions, this combined approach reduces the risk of misdiagnosis and helps ensure the correct, condition-specific treatment is started promptly.
Tests Available at NPL
Test Code | Test | Clinical Relevance |
I0178
| ANTI-NMO (NEUROMYELITIS OPTICA) ANTIBODY /AQUAPORIN 4, IFA | Aquaporin-4 (AQP4) antibody testing can support the evaluation of neuromyelitis optica spectrum disorder (NMOSD), particularly in patients with optic neuritis or longitudinally extensive transverse myelitis. |
I0179
| ANTI-MOG (MYELIN OLIGODENDROCYTE GLYCOPROTEIN), IFA | MOG antibody testing can support the evaluation of MOG-associated disease (MOGAD) in appropriate clinical settings, including optic neuritis, ADEM, and transverse myelitis. |
B0086
| IMMUNOGLOBULIN IGG SYNTHESIS INDEX & RATE | A cerebrospinal fluid-based investigation that may be used, in selected patients, to assess intrathecal (within the nervous system) antibody production as part of a broader neurological work-up. |
Most autoimmune antibody tests and inflammatory markers do not require fasting. However, if your doctor has ordered other tests at the same time — such as glucose or lipid testing — fasting may be required for those investigations. Please follow the preparation instructions provided by your doctor or NPL.
Home Sample Collection
NPL offers convenient home sample collection for all Demyelinating Disease tests, so you don't need to visit a lab in person.
→ Book your test online, via the NPL app, or by calling +977 1 5970147 and select a convenient time slot for home sample collection.
→ A certified and experienced NPL phlebotomist visits your home at the scheduled time, following strict hygiene and safety protocols.
→ Your sample is transported under controlled, monitored conditions to NPL's NABL ACCREDITED UNDER ISO 15189:2022 laboratory for processing.
→ Your digital report is delivered securely to your phone or email, along with access to download and share it as needed.
When to See a Doctor
• Sudden vision loss or eye pain, especially in one eye — seek urgent care
• New limb weakness or numbness — seek urgent care
• New bladder or bowel dysfunction with limb symptoms — seek urgent care
• Sudden confusion or multifocal neurological symptoms, particularly in a child — seek urgent care
• Known demyelinating disease with new or worsening neurological symptoms
Medical Disclaimer Laboratory tests are supportive tools and should not be used alone to diagnose or exclude demyelinating disease. Results should be interpreted by a qualified neurologist together with clinical history, examination, MRI findings, and, where appropriate, cerebrospinal fluid analysis. |